Sendero Wealth Management LLC Takes $725,000 Position in DexCom, Inc. (NASDAQ:DXCM)

Sendero Wealth Management LLC purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,619 shares of the medical device company's stock, valued at approximately $725,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Brighton Jones LLC increased its position in DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock worth $1,290,000 after acquiring an additional 11,946 shares during the period. Caprock Group LLC raised its holdings in DexCom by 86.0% in the 4th quarter. Caprock Group LLC now owns 6,515 shares of the medical device company's stock valued at $507,000 after buying an additional 3,012 shares during the last quarter. Heck Capital Advisors LLC bought a new position in shares of DexCom during the fourth quarter valued at $38,000. Tokio Marine Asset Management Co. Ltd. lifted its holdings in DexCom by 8.7% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 13,956 shares of the medical device company's stock worth $1,085,000 after buying an additional 1,115 shares during the period. Finally, DAVENPORT & Co LLC boosted its holdings in DexCom by 2.3% in the fourth quarter. DAVENPORT & Co LLC now owns 38,521 shares of the medical device company's stock valued at $2,996,000 after acquiring an additional 873 shares during the last quarter. Institutional investors own 97.75% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on DXCM shares. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Mizuho started coverage on DexCom in a research report on Thursday, April 10th. They set an "outperform" rating and a $85.00 target price for the company. Robert W. Baird reduced their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Barclays raised their price objective on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a report on Monday, May 5th. Finally, Piper Sandler reduced their target price on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Five analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, DexCom currently has a consensus rating of "Moderate Buy" and an average target price of $98.32.

Insider Buying and Selling at DexCom

In related news, COO Jacob Steven Leach sold 14,076 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the sale, the chief operating officer now directly owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. This represents a 4.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jereme M. Sylvain sold 7,000 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the sale, the executive vice president now owns 135,482 shares of the company's stock, valued at approximately $10,002,636.06. The trade was a 4.91% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 83,110 shares of company stock valued at $6,103,505 over the last quarter. Corporate insiders own 0.32% of the company's stock.

DexCom Trading Up 0.2%

Shares of NASDAQ:DXCM traded up $0.13 during midday trading on Thursday, reaching $85.74. 2,394,712 shares of the company's stock were exchanged, compared to its average volume of 4,337,558. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The firm's 50 day simple moving average is $75.64 and its two-hundred day simple moving average is $78.89. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $120.48. The stock has a market cap of $33.62 billion, a price-to-earnings ratio of 59.96, a P/E/G ratio of 2.30 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The firm had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. During the same quarter in the prior year, the firm posted $0.32 EPS. DexCom's quarterly revenue was up 12.5% compared to the same quarter last year. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.